GLP-1 receptor agonists (semaglutide, tirzepatide)

This is the strongest human evidence base in the longevity-clinic drug universe, but the strength sits in cardiometabolic disease, not in ageing. The SELECT trial (17,604 adults with overweight or obesity and established cardiovascular disease, no diabetes; ~40 months mean follow-up) found semaglutide 2.4 mg weekly cut the composite of cardiovascular death, non-fatal MI and non-fatal stroke by 20% (HR 0.80, 95% CI 0.72 to 0.90, p<0.001), with a supportive but hierarchically untested all-cause mortality signal (HR 0.81, 95% CI 0.71 to 0.93) and mean 9.4% weight loss. Reducing MACE and incident diabetes in a high-risk population is a genuine healthspan-relevant outcome, and that is what justifies a clinical grade. What the evidence does NOT show: no trial has demonstrated that GLP-1 RAs extend lifespan, and none was designed to. Ageing-specific data is early and small. A randomised placebo-controlled study reported semaglutide slowed one validated epigenetic clock by roughly 9%, and a UC San Diego pilot reported telomere lengthening in about half of treated participants over 24 weeks; these are surrogate biomarkers, not outcomes, in small samples, and epigenetic-clock movement has never been validated as a proxy for lifespan. The first trial explicitly powered for healthspan endpoints in healthy older adults, VITAL-H (ARPA-H funded, UT Health San Antonio), was only announced in February 2026 and has not reported. Critically, essentially all outcome evidence comes from populations with obesity, diabetes or established cardiovascular disease. There is no outcome evidence supporting use in metabolically healthy, normal-weight adults, which is precisely the longevity-clinic use case, and no evidence base at all for the "microdosing for longevity" protocols some clinics market. Loss of lean mass with weight loss is a real and under-discussed risk in older adults. Verdict: clinical for cardiometabolic and weight outcomes in indicated populations; mechanism-to-preclinical for any anti-ageing claim specifically.

What it is

Plain-language explainer

Categories

Common questions

What is GLP-1 receptor agonists (semaglutide, tirzepatide)?

This is the strongest human evidence base in the longevity-clinic drug universe, but the strength sits in cardiometabolic disease, not in ageing. The SELECT trial (17,604 adults with overweight or obesity and established cardiovascular disease, no diabetes; ~40 months mean follow-up) found semaglutide 2.4 mg weekly cut the composite of cardiovascular death, non-fatal MI and non-fatal stroke by 20% (HR 0.80, 95% CI 0.72 to 0.90, p<0.001), with a supportive but hierarchically untested all-cause mortality signal (HR 0.81, 95% CI 0.71 to 0.93) and mean 9.4% weight loss. Reducing MACE and incident diabetes in a high-risk population is a genuine healthspan-relevant outcome, and that is what justifies a clinical grade. What the evidence does NOT show: no trial has demonstrated that GLP-1 RAs extend lifespan, and none was designed to. Ageing-specific data is early and small. A randomised placebo-controlled study reported semaglutide slowed one validated epigenetic clock by roughly 9%, and a UC San Diego pilot reported telomere lengthening in about half of treated participants over 24 weeks; these are surrogate biomarkers, not outcomes, in small samples, and epigenetic-clock movement has never been validated as a proxy for lifespan. The first trial explicitly powered for healthspan endpoints in healthy older adults, VITAL-H (ARPA-H funded, UT Health San Antonio), was only announced in February 2026 and has not reported. Critically, essentially all outcome evidence comes from populations with obesity, diabetes or established cardiovascular disease. There is no outcome evidence supporting use in metabolically healthy, normal-weight adults, which is precisely the longevity-clinic use case, and no evidence base at all for the "microdosing for longevity" protocols some clinics market. Loss of lean mass with weight loss is a real and under-discussed risk in older adults. Verdict: clinical for cardiometabolic and weight outcomes in indicated populations; mechanism-to-preclinical for any anti-ageing claim specifically.

How strong is the evidence for GLP-1 receptor agonists (semaglutide, tirzepatide)?

Clinical. There is human trial evidence, which is the strongest grade variis applies to a protocol.

Is GLP-1 receptor agonists (semaglutide, tirzepatide) approved in Singapore?

Health Sciences Authority position on record: Registered with HSA, indication depends on the product. Wegovy (semaglutide 2.4 mg) is HSA-registered for weight management in adults with BMI >=30, or >=27 with a weight-related comorbidity, and for adolescents aged 12+ with obesity and body weight above 60 kg, plus an indication for reducing cardiovascular risk in those with established cardiovascular disease (Singapore National Drug Formulary, SIN16744P). Mounjaro (tirzepatide) is HSA-registered as SIN16714P (registrant DKSH Singapore) for adults with type 2 diabetes inadequately controlled by diet and exercise, as monotherapy where metformin is unsuitable or in combination; the government formulary entry retrieved lists ONLY the type 2 diabetes indication. Commercial Singapore clinic blogs claim HSA added a weight-management indication for Mounjaro in June 2025, but this could not be confirmed against any HSA or NDF source and should be treated as unverified. All are prescription-only medicines; not Medisave or MediShield Life claimable for weight management. HSA has also issued a safety review assessing possible suicidal ideation and self-harm signals with GLP-1 RAs.. An evidence grade and a regulatory approval are different questions.

Is GLP-1 receptor agonists (semaglutide, tirzepatide) approved in Australia?

Therapeutic Goods Administration position on record: TGA-registered, and unusually for this category, registered for weight management rather than used off-label. Semaglutide was first TGA-registered in 2019 as Ozempic for type 2 diabetes. Wegovy (semaglutide 2.4 mg) is ARTG-registered for chronic weight management and, from December 2024, for secondary prevention of cardiovascular events in people with overweight or obesity without diabetes. Tirzepatide (Mounjaro) was approved by the TGA on 11 September 2024 for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity, in adults with BMI >=30 or >=27 with at least one weight-related comorbidity, in addition to its existing type 2 diabetes registration. Neither Wegovy nor Mounjaro is PBS-subsidised for weight management; both are private prescription only. Note: the TGA's own ARTG and registration pages timed out on direct retrieval, so the indication wording and dates here are sourced from RACGP newsGP and Australian Prescriber rather than read off the TGA site directly.. An evidence grade and a regulatory approval are different questions.

Which clinics offer GLP-1 receptor agonists (semaglutide, tirzepatide)?

1 clinic in the variis directory across Singapore and Australia has GLP-1 receptor agonists (semaglutide, tirzepatide) on record. Each is listed on this page with its own sourced profile.

What else is GLP-1 receptor agonists (semaglutide, tirzepatide) called?

Also known as GLP-1 RA, semaglutide, Wegovy, Ozempic, tirzepatide, Mounjaro, GLP-1/GIP dual agonist, incretin mimetics.